ONCAlert | Upfront Therapy for mRCC

SABCS HER2-Negative Spotlight

A spotlight on HER2-negative breast cancer from the 2016 San Antonio Breast Cancer Symposium (SABCS) at the Henry B. Gonzalez Convention Center in San Antonio, Texas, from December 6 to December 10, 2016.

Encouraging Findings With Ribociclib in HR+ Breast Cancer

Encouraging Findings With Ribociclib in HR+ Breast Cancer

Harold J. Burstein, MD, PhD

Ribociclib Demonstrates Significant Benefit in Advanced Breast Cancer

Carboplatin Does Not Produce Greater Response Over Docetaxel in BRCA1 Methylated or Silenced TNBC

Wayne Kuznar

Continuous Low-Dose Ribociclib Active in Advanced Breast Cancer Causes Less Neutropenia

Wayne Kuzner

Pembrolizumab Continues to Show Durable Benefit in Heavily Pretreated TNBC

Silas Inman

Lead neoMONARCH Researcher Provides Insight on Abemaciclib Potential in HR-Positive Breast Cancer

Lead neoMONARCH Researcher Provides Insight on Abemaciclib Potential in HR-Positive Breast Cancer

Gina Columbus

MEK Inhibitor/Taxane Combination Active in Triple-Negative Breast Cancer

Advantages to Treating HR+ Patients With Breast Cancer With Abemaciclib

Advantages to Treating HR+ Patients With Breast Cancer With Abemaciclib

Hope S. Rugo, MD

SABCS HER2-Negative Spotlight

Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.